Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Sponsor: Regeneron Pharmaceuticals

Sponsor score: 60

ClinicalTrials ID:NCT07609940

This clinical trial evaluates the safety and efficacy of linvoseltamab with tocilizumab prophylaxis in RRMM patients. Eligible participants must have progressed after at least four prior therapies, including a PI, IMiD, and anti-CD38 antibody, and have an ECOG score ≤2. The study investigates side effects, CRS impact, and additional medication use. Linvoseltamab and tocilizumab are administered per protocol.

Patient Parameters

Program Overview

This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who have already been treated with at least four lines of treatment for their multiple myeloma, including medicines called a proteasome inhibitor, an immunomodulatory drug, and an anti-Cluster of Differentiation (CD) 38 antibody.

The aim of the study is to see how safe, tolerable and effective linvoseltamab is when given after tocilizumab.

The study is looking at several other research questions, including:

  • What side effects may happen from taking tocilizumab before the first dose of linvoseltamab
  • Whether tocilizumab has an impact on CRS, including whether participants require hospital care and, if so, how many hospital visits occur and how long they last
  • How frequently other medications (for example, corticosteroids or additional doses of tocilizumab) are used to support participants' care if needed

Eligibility Criteria

Inclusion Criteria

  1. Disease progression on or after at least 4 prior lines of therapy including a(n) Protease Inhibitor (PI), Immunomodulatory imide Drug (IMiD), and anti-CD 38 antibody
  2. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2
  3. Confirmed progressive disease according to IMWG criteria during or after the most recent line of therapy

Key

Exclusion Criteria

  1. Diagnosis of plasma cell leukemia, symptomatic amyloidosis (including myeloma-associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome
  2. Known myeloma brain lesions or meningeal involvement
  3. History of neurodegenerative condition, Progressive Multifocal Leukoencephalopathy [PML], or Central Nervous System (CNS) movement disorder

NOTE: Other protocol defined inclusion/exclusion criteria apply

Locations

FACILITYZIPCITYSTATE
Mary Bird Perkins Cancer Center70809Baton RougeLouisiana
Northwest Medical Specialties, PLLC98405TacomaWashington

Get This Program In Your Inbox

You can sign up and apply your patients for this program.